Drug intelligence / Profile preview

Mahuang Xuanfei Zhike

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Mahuang Xuanfei Zhike (MXZ) syrup is a Chinese patent medicine widely used for the clinical treatment of cough. It contains six core active components: ephedrine, amygdalin, chlorogenic acid, harpagoside, forsythin, and forsythoside A. A UPLC-MS/MS method has been established for the quantitative analysis of these components in biological samples, and pharmacokinetic and tissue distribution studies have shown that these active components are quickly absorbed and slowly eliminated in vivo, potentially involving a reabsorption process.

Other names: Mahuang Xuanfei Zhike syrup

Beyond the preview

Go deeper on Mahuang Xuanfei Zhike.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mahuang Xuanfei Zhike.

Explore the full profile